Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for cancer and rare diseases, appointed Kristin Yarema, company president, cell therapy.

“Kristin brings extensive biopharmaceutical experience in oncology and allogeneic T cell immunotherapy to Poseida, and I am excited to welcome her to our leadership team,” said Mark Gergen, CEO. “With her strategic, business and scientific background, she is a proven leader who has overseen all aspects of commercialization of product candidates across multiple therapeutic areas including the first approval of an allogeneic T cell therapy. Alongside our outstanding team, she will lead the execution of drug development programs in cell therapy, including our collaboration with Roche. I look forward to working with Kristin as we continue to focus on redefining cell and gene therapy for patients in need.”

Yarema has led product strategy and commercialization for therapies at all stages of their life cycle. She joins Poseida after most recently serving as chief commercial officer at Atara Biotherapeutics, where she led the commercialization of EBVALLO, which became the world’s first marketed allogeneic T cell therapy after receiving regulatory approval in Europe for the treatment of a rare lymphoma. In addition, Yarema drove product and portfolio strategy and commercialization for allogeneic pipeline therapies including CAR-Ts for liquid and solid tumors, as well as allogeneic T cell therapy for multiple sclerosis and other autoimmune diseases.

Prior to her time at Atara, she held a series of U.S. and global commercial leadership roles at Amgen, including most recently vice president & therapeutic area head for global product strategy & commercial innovation in hematology-oncology, where her work included CAR-T, T cell engagers, and other innovative therapies.